- Home
- EDRY vs MIRA Comparison
EDRY vs MIRA Comparison
Compare EDRY & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EDRY | MIRA |
|---|---|---|
| Founded | 2018 | 2020 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.9M | 33.7M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | EDRY | MIRA |
|---|---|---|
| Price | $12.90 | $1.51 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.7K | ★ 229.7K |
| Earning Date | 02-23-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $49,384,447.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $21.94 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.60 | $0.73 |
| 52 Week High | $16.14 | $2.45 |
Technical Indicators
Market Signals| Indicator | EDRY | MIRA |
|---|---|---|
| Relative Strength Index (RSI) | 46.05 | 50.81 |
| Support Level | $12.30 | $1.44 |
| Resistance Level | $13.39 | $1.51 |
| Average True Range (ATR) | 0.28 | 0.06 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 48.62 | 24.04 |
Price Performance
Historical ComparisonAbout EDRY EuroDry Ltd.
EuroDry Ltd is a holding company. It is a provider of ocean-going transportation. The company owns and operates dry bulk carriers that transport bulk such as iron ore, coal, and grains, and minor bulks such as bauxite, phosphate, and fertilizers. It operates under one operating and one reportable segment, that of operating dry bulk vessels.
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.